Fresh Start, page-53

People tend to forget why ANP appointed Dr. Gil Price as a Non-Executive Director...

Please refer to the past ASX Announcement on Oct 4th 2021.

"Gil’s ongoing engagement with Key Opinion Leaders in the treatment of DMD and DMD Patient Advocacy Groups has helped increase the awareness of the Company’s ATL1102 for DMD development program and to translate the features and benefits of the program to these audiences and to advocates internationally and in the capital markets. This important work has recently resulted in the Company being invited to be a member of the Pharmaceutical Advisory Board for the development of the New Duchenne Guidance by Parent Project Muscular Dystrophy (PPMD) for the US FDA."